IDOVEN
- Company typePrivate
- Founded2018
- HeadquartersMadrid, Spain
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
What IDOVEN does
IDOVEN 1903, S.L. (trading as Idoven) is a Madrid-based AI health technology company founded in 2018 that develops Willem, an AI-powered cardiology-as-a-service platform certified as a Class IIa Medical Device under EU MDR 2017/745. Willem applies deep neural networks trained on one of the industry's largest annotated ECG datasets — 1.8 million ECG hours and 28,500+ clinical trial subjects — to detect 22 cardiac patterns and 4 intervals (P, PR, QT, and QRS) across ambulatory, 12-lead, and Insertable Cardiac Monitor devices. The platform is device-neutral, supports EDF, HL7, DICOM, JSON, XML, and PDF inputs, and exposes bi-directional API integration with Electronic Health Record and Home Monitoring systems.
The company operates a multi-segment B2B go-to-market anchored on direct enterprise sales. It serves MedTech companies with digital diagnostics and ECG interpretation, Life Sciences and pharmaceutical firms with digital biomarkers, prediction models, cardiotoxicity monitoring, risk stratification, and pre-initiation ECG testing for clinical trials, and corporate health buyers with continuous remote preventative screening programs. A consumer-facing iOS app, Donate Your Heartbeats, captures Apple Watch ECG data for research. Pricing is quote-based, and the company collaborates with 17 EU and US research centres across 20+ countries and has secured strategic relationships with named anchors including AstraZeneca (CONCERTO amyloidosis programme), Abbott, GE Healthcare, and Medtronic.
Revenue mechanics are predominantly recurring subscription or software arrangements supplemented by pharma pre-initiation professional services. The company is privately held and venture-backed, having raised approximately $19.5M in Series A funding in mid-2022 led by Insight Partners and Northzone, complemented by EIC grants (notably $6.85M in 2022), EIT Health funding ($1.65M in 2023), and a subsequent undisclosed round from Northzone and Insight Partners in September 2023 to fund geographic expansion and solution development. Recent operational milestones include the 2024 acquisition of NVIDIA DGX H100 systems for AI training acceleration, the 2025 launch of the CONCERTO project with AstraZeneca for early amyloidosis diagnosis, and the 2025 release of the Donate Your Heartbeats consumer app.
IDOVEN firmographics
Firmographics- Name
- IDOVEN
- Legal name
- IDOVEN 1903, S.L.
- Website
- https://idoven.ai
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
IDOVEN industry classification
Industry- Product category
- AI Cardiac Diagnostics Software
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration) (HLACAPAI)
- akta.pro secondary industries
- Imaging & Cardiac Safety Core Labs (ECOG/EEG/ECG) (HLAGAAAJ), Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders) (HLAHACAB), Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA)
Keywords
Where IDOVEN is headquartered
LocationHeadquarters
- HQ city
- Madrid
- HQ country
- Spain
- HQ region
- Europe
Offices1 record
Markets served
IDOVEN business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations
Revenue model
- MedTech Diagnostics Solutions: B2B revenue from providing AI-powered ECG interpretation solutions to MedTech companies for digital diagnostics, cloud technology, and deep neural network analysis to reduce time and expense associated with ECG interpretation.
- Life Sciences Solutions: Revenue from pharmaceutical and life sciences companies for digital biomarkers, prediction models, cardiotoxicity monitoring, and risk stratification using ECG-based solutions.
- Preventative Screening Programs: Continuous remote ECG monitoring services for organizations to manage employee health and wellbeing, providing medical-grade reports through proprietary algorithms and cardiologists.
- Pharma Pre-Initiation ECG Testing: ECG testing services for pharmaceutical companies during pre-initiation phases of clinical trials.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels8 records
IDOVEN product offering
Product offeringCore offering
IDOVEN develops and sells Willem, an AI-powered cardiology-as-a-service platform certified as a Class IIa Medical Device under EU MDR 2017/745, which uses deep neural networks to automatically detect 22 cardiac patterns and 4 ECG intervals from recordings of 30 seconds to 30 days. The platform is offered to MedTech companies, Life Sciences/pharmaceutical firms, and corporate health programs via subscription and API, with vertical solutions for digital diagnostics, digital biomarkers, cardiotoxicity monitoring, and preventative screening. A consumer-facing Donate Your Heartbeats iOS app captures Apple Watch ECG data to enrich the proprietary training database.
Product overview
IDOVEN operates a platform-plus-modules architecture centered on Willem, the world's first AI-powered cardiology-as-a-service platform certified as a Medical Device Class IIa (EU MDR). Willem provides automated ECG analysis detecting 22 cardiac patterns and 4 intervals for clinical decision support. The portfolio includes Willem Workspace (Class I medical device for signal visualization/labelling), vertical solutions for MedTech (digital diagnostics), Life Sciences (digital biomarkers and cardiotoxicity), pharma (Pre-Initiation ECG Testing), and preventative screening programs. Consumer-facing offerings include the Donate Your Heartbeats iOS app for contributing ECG data to research. The CONCERTO project with AstraZeneca focuses on early amyloidosis detection. All solutions are device-neutral and support integration with EHR systems, home monitoring, and various ECG device types.
Differentiator
Problem solved
Functional benefit
Brands
- Willem: AI-powered ECG analysis platform certified as Medical Device Class IIa under EU MDR 2017/745, capable of detecting 22 cardiac patterns and 4 intervals (P Interval, PR Interval, QT Interval, and QRS duration) across various ECG recording device types.
- Willem Workspace
- Donate Your Heartbeats
- CONCERTO
Products and services
- Willem ECG Analysis Platform AI-powered cardiology-as-a-service platform certified as a Class IIa Medical Device under EU MDR 2017/745 that automatically detects 22 cardiac patterns and 4 ECG intervals (P, PR, QT, QRS) across ambulatory ECG (holter/patch, 1- and 2-lead), standard 12-lead diagnostic ECG, and Insertable Cardiac Monitors. Delivered to MedTech, Life Sciences, and pharma customers via API and non-API tools for scalable triage and diagnosis.
- For MedTech Solution Digital diagnostics solution for MedTech companies that enables rapid and accurate identification of arrhythmias and cardiac patterns, significantly reducing time and expense of ECG interpretation through cloud technology, deep neural network analysis, and vendor-neutral integration with Home Monitoring and EHR systems.
- For Life Sciences Solution Solution for pharmaceutical and life sciences companies providing ECG-based digital biomarkers, prediction models, cardiotoxicity assessment, and risk stratification to identify high-risk, undiagnosed, or undertreated patients and monitor cardiac drug safety.
- Preventative Screening Programs Continuous remote ECG monitoring and preventative screening program for organizations, combining proprietary algorithms with cardiologist analysis to deliver medical-grade reports from non-invasive ECG devices worldwide.
- Pre-Initiation ECG Testing for Pharma ECG testing service for pharmaceutical companies conducting pre-initiation cardiac safety assessment during clinical trial preparation, leveraging Willem's arrhythmia detection and biomarker capabilities.
- Willem Workspace Self-certified Class I Medical Device workspace tool that visualizes and labels electrical heart activity signals, highlighting arrhythmia and electrocardiographic patterns to support clinical decision-making, used alongside the Willem ECG analysis platform.
Quantifiable outcome
- Analysis time reduced from hours to minutes
- +3 more outcomes
Companies that use IDOVEN
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles3 records
IDOVEN technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
Integration9 records
AI capability5 records
Feature7 records
IDOVEN partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core, key and supportive.
- AstraZenecacoreAstraZeneca and Idoven launched the CONCERTO project to improve early diagnosis of amyloidosis using AI-powered cardiology. This strategic collaboration focuses on advancing cardiac care through AI-powered detection and precision medicine.
- NVIDIAcoreIdoven acquired NVIDIA DGX H100 systems to enhance AI-powered cardiac diagnostics. This investment accelerates the training and validation of their AI models (Willem) to improve accuracy and speed of diagnosing cardiovascular diseases.
- EIT HealthcoreEIT Health funded the ASSIST project led by Idoven with €1.5 million to develop an AI-based solution for early diagnosis of myocardial infarction. The project aims to improve diagnostic accuracy, reduce detection time, potentially reaching over 1.2 million patients in three years.
- Iker CasillaskeyWorld Cup-winning goalkeeper and UN Goodwill ambassador who suffered a heart attack in 2019. He relies on Idoven for heart care and serves as investor and ambassador, partnering with the Iker Casillas Foundation to impact lives of vulnerable groups at high risk of cardiovascular diseases.
- Pau GasolkeyOlympic basketball player serving as ambassador for Idoven and the Donate Your Heartbeats movement to advance research in prevention of heart attacks, strokes and cardiovascular diseases.
- Google for StartupssupportiveIdoven is hosted at Google for Startups Campus in Madrid, recognized and supported by Google's startup ecosystem for technology companies.
- EU and US Research Centers (MAESTRIA H2020)core17 collaborators from leading EU and US research centres and industry partners on stroke and atrial fibrillation research as part of the MAESTRIA H2020 project.
Scale indicators11 records
Recent moves6 records
Expansion highlights6 records
IDOVEN competitors and assessment
Company assessmentDirect peers
- Cardiologs (Philips): AI-based ECG interpretation platform serving clinicians and hospitals; acquired by Philips in 2021. Direct functional overlap with IDOVEN's Willem in cloud-based ECG pattern detection and arrhythmia classification for enterprise healthcare customers.
- Eko Health: AI-powered cardiac analysis combining digital stethoscopes and ECG with FDA-cleared algorithms for heart murmur and AF detection. Comparable to IDOVEN in applying deep learning to cardiac signals and selling to clinicians and health systems.
- AliveCor: Maker of KardiaMobile ECG devices and AI-based arrhythmia interpretation, with both D2C and B2B distribution. Overlaps with IDOVEN in AI-ECG pattern detection, though IDOVEN's model is device-neutral and B2B-focused while AliveCor ships its own hardware.
- Anumana: ECG-AI platform spun out of the Mayo Clinic with FDA-cleared algorithms for cardiac diagnostics, including cardiac amyloidosis. Direct overlap with IDOVEN's Willem on AI-enabled ECG interpretation for clinical decision support, with strong clinical validation in cardiology.
- UltraSight: AI guidance for cardiac ultrasound/echocardiography, applying deep learning to a different cardiac signal modality. Comparable in spirit to IDOVEN as a cardiac AI software vendor building a clinician-facing diagnostic platform.
Broad incumbents
- HeartFlow: Established AI-driven cardiac diagnostics company with FDA-cleared FFR-CT analysis for coronary disease. Broader and more clinically embedded than IDOVEN, but addresses the same AI-for-cardiology enterprise market segment.
- iRhythm Technologies: Public company behind the Zio long-term cardiac monitoring patch and associated AI arrhythmia classification. Compares to IDOVEN as a cardiac-monitoring franchise, but with proprietary hardware and a US commercial footprint rather than a device-neutral software model.
- Tempus AI: Large AI-driven precision medicine platform with a cardiology and real-world evidence business. Relevant to IDOVEN's Life Sciences and cardiotoxicity offerings as a much broader competitor spanning multiple therapeutic areas.
- Viz.ai: AI clinical workflow platform with a strong cardiology module (aortic stenosis, heart failure) sold to hospital systems. Adjacent to IDOVEN's enterprise cardiology AI motion but broader in scope and modality (imaging + workflow) rather than ECG-centric.
Emerging players
- Cleerly: AI-enabled cardiac CT analysis focused on coronary plaque and risk stratification. Adjacent to IDOVEN's digital biomarker / risk prediction roadmap rather than direct ECG overlap, but competes for the same pharma and provider budget for cardiac AI.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
IDOVEN social profiles
Digital presenceIDOVEN compliance and trust
Trust signalCompliance13 records
IDOVEN financial estimates
Financial estimateRevenue estimate
Valuation estimate
IDOVEN leadership team
Management profileNumber of profiles
Profiles3 records
IDOVEN funding detail
Funding detailFunding overview
Funding rounds7 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
IDOVEN M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about IDOVEN
What does IDOVEN do?
IDOVEN develops and sells Willem, an AI-powered cardiology-as-a-service platform certified as a Class IIa Medical Device under EU MDR 2017/745, which uses deep neural networks to automatically detect 22 cardiac patterns and 4 ECG intervals from recordings of 30 seconds to 30 days. The platform is offered to MedTech companies, Life Sciences/pharmaceutical firms, and corporate health programs via subscription and API, with vertical solutions for digital diagnostics, digital biomarkers, cardiotoxicity monitoring, and preventative screening. A consumer-facing Donate Your Heartbeats iOS app captures Apple Watch ECG data to enrich the proprietary training database.
Is IDOVEN a public or private company?
IDOVEN is a private company. It is classified as venture growth investor backed and is currently operating.
When was IDOVEN founded?
IDOVEN was founded in 2018. It employs 51 to 100 people.
Where is IDOVEN based?
IDOVEN is headquartered in Madrid, Spain, in the Europe region.
How does IDOVEN make money?
Four revenue lines are on record. MedTech Diagnostics Solutions are the primary driver. The others are life Sciences Solutions, preventative Screening Programs and pharma Pre-Initiation ECG Testing.
Who are IDOVEN's main competitors?
Direct peers on record are Cardiologs (Philips), Eko Health, AliveCor, Anumana and UltraSight. Broad incumbents are HeartFlow, iRhythm Technologies, Tempus AI and Viz.ai. Cleerly is listed as an emerging player.
Does IDOVEN have an API?
Yes. IDOVEN provides API access to their Willem ECG analysis platform, enabling bi-directional data exchange with customer systems. The solution is device neutral and made available via API and non-API tools. Ingests data from standard and proprietary formats including EDF, HL7, DICOM, JSON, XML, PDF. Supports ECG analysis from 30 seconds to 30 days duration. Developer documentation is at willem-api.idoven.ai/doc.
What industry is IDOVEN in?
IDOVEN's product category is AI Cardiac Diagnostics Software. Its primary akta.pro industry code is HLACAPAI, Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration), with a secondary code of HLAGAAAJ, Imaging & Cardiac Safety Core Labs (ECOG/EEG/ECG). Its NAICS code is 334510 and its SIC code is 3845.